請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32836完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 余家利(Chia-Li Yu) | |
| dc.contributor.author | Yu-Lin Tzeng | en |
| dc.contributor.author | 曾玉霖 | zh_TW |
| dc.date.accessioned | 2021-06-13T04:16:46Z | - |
| dc.date.available | 2011-08-03 | |
| dc.date.copyright | 2006-08-03 | |
| dc.date.issued | 2006 | |
| dc.date.submitted | 2006-07-25 | |
| dc.identifier.citation | 1. Pfleiderer, A. Diagnosis and staging of ovarian cancer. J Cancer Res Clin Oncol, 107: 81-88, 1984.
2. Gonzalez-Diego, P., Lopez-Abente, G., Pollan, M., and Ruiz, M. Time trends in ovarian cancer mortality in Europe (1955-1993): effect of age, birth cohort and period of death. Eur J Cancer, 36: 1816-1824, 2000. 3. Tarone, R. E. and Chu, K. C. Age-period-cohort analyses of breast-, ovarian-, endometrial- and cervical-cancer mortality rates for Caucasian women in the USA. J Epidemiol Biostat, 5: 221-231, 2000. 4. Parkin, D. M., Pisani, P., and Ferlay, J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer, 54: 594-606, 1993. 5. Beard, C. M., Hartmann, L. C., Atkinson, E. J., O'Brien, P. C., Malkasian, G. D., Keeney, G. L., and Melton, L. J., 3rd The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935-1991. Ann Epidemiol, 10: 14-23, 2000. 6. Boyle, P., Maisonneuve, P., and Autier, P. Update on cancer control in women. Int J Gynaecol Obstet, 70: 263-303, 2000. 7. Gonzalez-Diego, P., Lopez-Abente, G., Pollan, M., and Ruiz, M. Time trends in ovarian cancer mortality in europe (1955-1993). effect Of age, birth cohort and period of death [In Process Citation]. Eur J Cancer, 36: 1816-1824, 2000. 8. Rustin, G. J. Tumour markers for ovarian cancer. Eur J Cancer, 28: 2-3, 1992. 9. Sorbe, B., Frankendal, B., and Veress, B. Importance of histologic grading in the prognosis of epithelial ovarian carcinoma. Obstet Gynecol, 59: 576-582, 1982. 10. Hacker, N. F., Berek, J. S., Lagasse, L. D., Nieberg, R. K., and Elashoff, R. M. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol, 61: 413-420, 1983. 11. Malkasian, G. D., Jr., Melton, L. J., 3rd, O'Brien, P. C., and Greene, M. H. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol, 149: 274-284, 1984. 12. Swenerton, K. D., Hislop, T. G., Spinelli, J., LeRiche, J. C., Yang, N., and Boyes, D. A. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol, 65: 264-270, 1985. 13. Jacobs, I. and Bast, R. C., Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod, 4: 1-12, 1989. 14. Mazurek, A., Niklinski, J., Laudanski, T., and Pluygers, E. Clinical tumour markers in ovarian cancer. Eur J Cancer Prev, 7: 23-35, 1998. 15. Berek, J. S. and Bast, R. C., Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer, 76: 2092-2096, 1995. 16. Guadagni, F., Roselli, M., Cosimelli, M., Ferroni, P., Spila, A., Cavaliere, F., Casaldi, V., Wappner, G., Abbolito, M. R., Greiner, J. W., and et al. CA 72-4 serum marker--a new tool in the management of carcinoma patients. Cancer Invest, 13: 227-238, 1995. 17. Pannek, J. and Partin, A. W. The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer. Semin Urol Oncol, 16: 100-105, 1998. 18. Hunerbein, M. The value of tumor markers in colorectal cancer. Recent Results Cancer Res, 146: 48-55, 1998. 19. Posner, M. R. and Mayer, R. J. The use of serologic tumor markers in gastrointestinal malignancies. Hematol Oncol Clin North Am, 8: 533-553, 1994. 20. Rubach, M., Szymendera, J. J., Kaminska, J., and Kowalska, M. Serum CA 15.3, CEA and ESR patterns in breast cancer. Int J Biol Markers, 12: 168-173, 1997. 21. Chang, K. and Pastan, I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A, 93: 136-140, 1996. 22. Yamaguchi, N., Hattori, K., Oh-eda, M., Kojima, T., Imai, N., and Ochi, N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem, 269: 805-808, 1994. 23. Chang, K., Pastan, I., and Willingham, M. C. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer, 50: 373-381, 1992. 24. Hough, C. D., Sherman-Baust, C. A., Pizer, E. S., Montz, F. J., Im, D. D., Rosenshein, N. B., Cho, K. R., Riggins, G. J., and Morin, P. J. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res, 60: 6281-6287, 2000. 25. Sobin LH, W. C. UICC TNM Classification of Malignant Tumors, 5th ed. New York, New York: Wiley iss, 1997. 26. Scholler, N., Fu, N., Yang, Y., Ye, Z., Goodman, G. E., Hellstrom, K. E., and Hellstrom, I. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A, 96: 11531-11536, 1999. 27. Cheng, W. F., Hung, C. F., Chai, C. Y., Hsu, K. F., He, L., Rice, C. M., Ling, M., and Wu, T. C. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J Immunol, 166: 6218-6226, 2001. 28. Bera, T. K. and Pastan, I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol, 20: 2902-2906, 2000. 29. Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., and Kallioniemi, O. P. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med, 4: 844-847, 1998. 30. Mok, S. C., Chao, J., Skates, S., Wong, K., Yiu, G. K., Muto, M. G., Berkowitz, R. S., and Cramer, D. W. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst, 93: 1458-1464, 2001. 31. Wang, K., Gan, L., Jeffery, E., Gayle, M., Gown, A. M., Skelly, M., Nelson, P. S., Ng, W. V., Schummer, M., Hood, L., and Mulligan, J. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene, 229: 101-108, 1999. 32. Bast, R. C., Jr., Feeney, M., Lazarus, H., Nadler, L. M., Colvin, R. B., and Knapp, R. C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest, 68: 1331-1337, 1981. 33. Bast, R. C., Jr., Klug, T. L., St John, E., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., Zurawski, V. R., Jr., and Knapp, R. C. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med, 309: 883-887, 1983. 34. Meyer, T. and Rustin, G. J. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer, 82: 1535-1538, 2000. 35. Chen, C. A., Cheng, W. F., Lee, C. N., Chen, T. M., Kung, C. C., Hsieh, F. J., and Hsieh, C. Y. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol, 74: 235-240, 1999. 36. Tuxen, M. K., Soletormos, G., and Dombernowsky, P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev, 21: 215-245, 1995. 37. Mills, G. B., Bast, R. C., Jr., and Srivastava, S. Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J Natl Cancer Inst, 93: 1437-1439, 2001. 38. Robertson, D. M., Stephenson, T., Pruysers, E., Burger, H. G., McCloud, P., Tsigos, A., Groome, N., Mamers, P., McNeilage, J., Jobling, T., and Healy, D. Inhibins/activins as diagnostic markers for ovarian cancer. Mol Cell Endocrinol, 191: 97-103, 2002. 39. Gadducci, A., Zola, P., Landoni, F., Maggino, T., Sartori, E., Bergamino, T., and Cristofani, R. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol, 58: 42-47, 1995. 40. Tate, S., Hirai, Y., Takeshima, N., and Hasumi, K. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. Gynecol Oncol, 96: 143-149, 2005. 41. Hassan, R., Viner, J. L., Wang, Q. C., Margulies, I., Kreitman, R. J., and Pastan, I. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. J Immunother, 23: 473-479, 2000. 42. Hassan, R., Lerner, M. R., Benbrook, D., Lightfoot, S. A., Brackett, D. J., Wang, Q. C., and Pastan, I. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res, 8: 3520-3526, 2002. 43. Sato, N., Fukushima, N., Maitra, A., Iacobuzio-Donahue, C. A., van Heek, N. T., Cameron, J. L., Yeo, C. J., Hruban, R. H., and Goggins, M. Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol, 164: 903-914, 2004. 44. Iacobuzio-Donahue, C. A., Ashfaq, R., Maitra, A., Adsay, N. V., Shen-Ong, G. L., Berg, K., Hollingsworth, M. A., Cameron, J. L., Yeo, C. J., Kern, S. E., Goggins, M., and Hruban, R. H. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res, 63: 8614-8622, 2003. 45. Ryu, B., Jones, J., Blades, N. J., Parmigiani, G., Hollingsworth, M. A., Hruban, R. H., and Kern, S. E. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res, 62: 819-826, 2002. 46. Argani, P., Iacobuzio-Donahue, C., Ryu, B., Rosty, C., Goggins, M., Wilentz, R. E., Murugesan, S. R., Leach, S. D., Jaffee, E., Yeo, C. J., Cameron, J. L., Kern, S. E., and Hruban, R. H. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res, 7: 3862-3868, 2001. 47. Swierczynski, S. L., Maitra, A., Abraham, S. C., Iacobuzio-Donahue, C. A., Ashfaq, R., Cameron, J. L., Schulick, R. D., Yeo, C. J., Rahman, A., Hinkle, D. A., Hruban, R. H., and Argani, P. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol, 35: 357-366, 2004. 48. Antonescu, C. R., Viale, A., Sarran, L., Tschernyavsky, S. J., Gonen, M., Segal, N. H., Maki, R. G., Socci, N. D., DeMatteo, R. P., and Besmer, P. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res, 10: 3282-3290, 2004. 49. Robinson, B. W., Creaney, J., Lake, R., Nowak, A., Musk, A. W., de Klerk, N., Winzell, P., Hellstrom, K. E., and Hellstrom, I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet, 362: 1612-1616, 2003. 50. Frierson, H. F., Jr., Moskaluk, C. A., Powell, S. M., Zhang, H., Cerilli, L. A., Stoler, M. H., Cathro, H., and Hampton, G. M. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol, 34: 605-609, 2003. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32836 | - |
| dc.description.abstract | 目的：研究血清中mesothelin和臨床病理因子之間的關係，並且檢驗mesothelin 是否可成為檢測卵巢癌的生物標記和獨立的預後因子。
方法：本研究涵蓋24位正常者、20位有良性卵巢症狀的婦女、以及122位罹患卵巢上皮細胞癌者，記錄其臨床及病理項目。以酵素連結免疫吸附法(ELISA)檢測這些婦女其血清檢體於治療前的mesothelin和CA125，分析檢測之血清mesothelin和CA125結果與病人的臨床及病理數據是否呈現相關性。我們進一步比較和評估組織病理學項目、血清中meosthelin和CA125對病人預後的影響。 結果：卵巢癌病患於手術前的血清mesothelin值較高於良性卵巢病灶或正常者(OD450吸光值比分別為2.465、1.384 和 0.912)。在比較卵巢癌患者手術前的血清mesothelin方面，從卵巢癌第一期到第四期相較也呈顯著性增加。在122位卵巢癌病患中，其治療前血清mesothelin過量表現者(1.51 (1.02-2.24)和卵巢癌後期患者(1.61 (1.03-2.49)) (相對危險性(95%信賴區間))，皆顯示出明顯較差的整體存活率(Overall Survival)。此外在83位經適當的減積手術(debulking surgery)的卵巢癌病患(1.59 (1.02-2.48))以及79位卵巢癌後期病患(2.18 (1.09-4.38))當其治療前血清mesothelin過量表現者其整體存活率(OS) 也明顯較差。 結論：治療前的血清mesothelin可以被視為一個新的腫瘤標記，作為卵巢上皮細胞癌的鑑別診斷以及預測卵巢癌病患預後的因子。 | zh_TW |
| dc.description.abstract | Objective. To investigate the relationship between serum mesothelin and clinico-pathological factors, and to determine whether mesothelin is a biomarker for detection and an independent prognostic factor of ovarian cancer.
Methods. Twenty-four normal populations, 20 women with benign ovarian lesion, or 122 patients with epithelial ovarian cancer were enrolled. Clinical and pathologic items were recorded. Pretreatment mesothelin and CA125 serum samples of these women were measured by an enzyme-linked immunosorbent assay. The results were correlated to clinical data. The histopathologic items and serum meosthelin, and CA125 influencing clinical outcome were evaluated comparatively. Results. The preoperative serum levels of mesothelin (OD450 ratio) (2.465 vs. 1.384 vs. 0.912) were higher in ovarian cancer patients than in those with benign ovarian lesions or normal populations. The preoperative serum levels of mesothelin also significantly increased from stage I to IV. Elevated mesothelin serum levels before therapy (1.51 (1.02-2.24), Relative risk (95%CI)) and advanced stages (1.61 (1.03-2.49)) showed significantly poorer overall survival (OS) for 122 cancer patients. Elevated mesothelin serum levels before therapy also revealed significantly poorer OS for 83 cancer patients with optimal debulking surgery (1.59 (1.02-2.48)) and for 79 advanced-staged cancer patients (2.18 (1.09-4.38)). Conclusions. Pretreatment mesothelin serum levels might be regarded a new tumor marker for the differential diagnosis of ovarian cancer and an additional prognostic factor in predicting the outcome of ovarian carcinoma patients. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T04:16:46Z (GMT). No. of bitstreams: 1 ntu-95-P93448012-1.pdf: 563062 bytes, checksum: 7e109d922fd91d98e70200d2748acafe (MD5) Previous issue date: 2006 | en |
| dc.description.tableofcontents | 一、中文摘要.............................................1
二、英文摘要.............................................2 三、前言.................................................4 四、材料及方法...........................................6 五、結果.................................................8 六、討論................................................11 七、參考文獻............................................14 八、圖表................................................20 | |
| dc.language.iso | zh-TW | |
| dc.subject | 篩選標記 | zh_TW |
| dc.subject | 卵巢癌 | zh_TW |
| dc.subject | screening marker | en |
| dc.subject | ovarian cancer | en |
| dc.title | 卵巢上皮細胞癌(Epithelial Ovarian Cancer)血清中Mesothelin: 一個新的篩選標記和預後因子 | zh_TW |
| dc.title | Serum Mesothelin in Epithelial Ovarian Cancer: a New Screening Marker and Prognostic Factor | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 94-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 鄭文芳(Wen-Fang Cheng) | |
| dc.contributor.oralexamcommittee | 陳祈安(Chi-An Chen) | |
| dc.subject.keyword | 卵巢癌,篩選標記, | zh_TW |
| dc.subject.keyword | ovarian cancer,screening marker, | en |
| dc.relation.page | 26 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2006-07-25 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
| 顯示於系所單位： | 分子醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-95-1.pdf 未授權公開取用 | 549.87 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。